Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02950259 · ClinicalTrials.gov registry record · Phase 1
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
A Phase 1 study, sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02950259 is a Phase 1 study that has completed, run by Providence Health & Services. The registered enrollment target is 16 participants.
The verdict
NCT02950259, a Phase 1 study, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The goal of this study is assess the safety and tolerability of the IRX-2 regimen in patients with early stage breast cancer (ESBC) and to estimate the pathologic complete response rate to neoadjuvant anthracycline-based and non-platinum containing chemotherapy in patients with triple-negative breast cancer who have received the IRX-2 Regimen before chemotherapy.
Interventions
- DRUG Cyclophosphamide
- DRUG Indomethacin
- DRUG Omeprazole
- DIETARY_SUPPLEMENT Multivitamin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-02-09 |
| Est. Completion | 2025-09-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02950259
The ClinicalTrials.gov registry entry for NCT02950259 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02950259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02950259 about?
NCT02950259 is a clinical study titled "Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)". The goal of this study is assess the safety and tolerability of the IRX-2 regimen in patients with early stage breast cancer (ESBC) and to estimate the pathologic complete response rate to neoadjuvant anthracycline-based and non-platinum containing chemotherapy in patients with triple-negative breas...
What is the current status of trial NCT02950259?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2017-02-09. Estimated completion is 2025-09-25.
What interventions are being tested in trial NCT02950259?
The interventions under investigation include: Cyclophosphamide (DRUG), Indomethacin (DRUG), Omeprazole (DRUG), Multivitamin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02950259?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.